ArticleAdvanced functional materials2025
Development of Nanocarrier-Based Oral Pegfilgrastim Formulations for Mitigating Hematopoietic Acute Radiation Syndrome.
Article in Advanced functional materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Multifunctional Polyphenol-Polymer Nanocomposite Hydrogel Targeting Inflammation, Oxidative Stress, and Infection in Diabetic Wounds.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Biomimetic Polymerization of Tellurocysteine: Breaking the Natural Amino Acid Radioprotection Limitation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Application of New Approach Methodologies to Improve Oral Biopharmaceutic Assessments.Pharmaceutics · 2026Review
- 3D printing- and cyclic strain-driven engineering of skeletal muscle blocks using enhanced viscoelastic extracellular matrix bioink.Materials today. Bio · 2026Article
- Synergistic nanomedicine overcomes hypoxia-driven DNA repair to potentiate radiotherapy for lung adenocarcinoma.Theranostics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
The increasing risks of ionizing radiation from deep space travel and nuclear accidents necessitate the development of effective countermeasures. Acute radiation syndrome (ARS), particularly hematopoietic ARS (H-ARS), leads to life-threatening anemia and bone marrow failure, with long-term risks including cancer and cardiovascular disease. This study presents phenylboronic acid-functionalized chitosan-polyethylenimine (CPB) polymers designed for efficient oral delivery of pegfilgrastim (PF), an FDA-approved radioprotective agent. Nanoparticles were prepared through complexation of PF with tannic acid, forming a negatively charged core, followed by encapsulation with a CPB polymer shell. This supramolecular strategy enabled efficient protein condensation into uniform nanoparticles. The nanosystem effectively reduced H-ARS-associated anemia in mice by promoting blood cell reconstitution, supported by
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.